Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2007 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: PLAVIX

« Back to Dashboard
Plavix is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from twelve suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PLAVIX is clopidogrel bisulfate. There are fourty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the clopidogrel bisulfate profile page.

Summary for Tradename: PLAVIX

Suppliers: see list12

Pharmacology for Tradename: PLAVIX

Clinical Trials for: PLAVIX

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.
Status: Completed Condition: Coronary Artery Disease

Clopidogrel Bioequivalence Study in Healthy Subjects
Status: Completed Condition: Bioequivalence, AUC, Cmax, Pharmacokinetics

Clopidogrel PGX Bench to Bedside
Status: Completed Condition: Metabolism of Clopidogrel

Aspirin and Plavix Following Coronary Artery Bypass Grafting
Status: Recruiting Condition: Coronary Graft Patency

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Status: Completed Condition: Healthy

Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Status: Recruiting Condition: Diabetes Type 2; Diabetic Nephropathy; Vascular Disease

Clopidogrel Pharmacogenomics Project
Status: Completed Condition: Disease Susceptibility

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Status: Not yet recruiting Condition: CLOPIDOGREL, POOR METABOLISM of (Disorder)

Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
Status: Recruiting Condition: Antiplatelet Agents

Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel
Status: Completed Condition: Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel; Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Sanofi Aventis Us
clopidogrel bisulfate
TABLET; ORAL020839-002Sep 20, 2007RXNo<disabled><disabled>
Sanofi Aventis Us
clopidogrel bisulfate
TABLET; ORAL020839-001Nov 17, 1997RXYes6,504,030<disabled><disabled>
Sanofi Aventis Us
clopidogrel bisulfate
TABLET; ORAL020839-001Nov 17, 1997RXYes<disabled><disabled>
Sanofi Aventis Us
clopidogrel bisulfate
TABLET; ORAL020839-001Nov 17, 1997RXYes4,847,265<disabled><disabled>
Sanofi Aventis Us
clopidogrel bisulfate
TABLET; ORAL020839-001Nov 17, 1997RXYes6,429,210<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PLAVIX

Drugname Dosage Strength RLD Submissiondate
clopidogrel bisulfateTablets300 mgPlavix3/4/2009
« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn